# GOG Foundation

Source: https://onco.cc/companies/gog-foundation/  
OnCo record `gog-foundation` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The US gynaecologic oncology trials organisation whose GOG-3000-series trials with industry brought immunotherapy into endometrial and cervical cancer.

## Summary

The Gynecologic Oncology Group was founded in 1970 as an NCI cooperative group and merged into NRG Oncology in 2014; the GOG Foundation continues as an independent organisation running industry-partnered trials through GOG Partners and supporting NRG's gynaecologic portfolio. GOG-0218 established bevacizumab in first-line ovarian cancer, and the GOG-3000 series includes RUBY (dostarlimab, GOG-3031), NRG-GY018/KEYNOTE-868 (pembrolizumab, GOG-3041), KEYNOTE-A18 (GOG-3047) in cervical cancer and MIRASOL (mirvetuximab, GOG-3045). It is a founding member of the Gynecologic Cancer InterGroup and partners with ENGOT groups such as GINECO. Most US gynaecologic oncology fellowships train through GOG sites.

## Fields

- Kind: Company
- Last checked: 2026-09-09
- Also known as: Gynecologic Oncology Group; GOG; GOG Partners
- Tags: cooperative-group
- HQ: Philadelphia, PA
- Type: cooperative-group
- Website: https://www.gog.org

## Notes

- GOG Partners industry trials (GOG-3000 series)
- RUBY, NRG-GY018 and KEYNOTE-A18
- GOG-0218 (bevacizumab)
- Gynecologic Cancer InterGroup

## Sources

- GOG Foundation: https://www.gog.org

## Connected records

- drugs: [Dostarlimab](https://onco.cc/drugs/dostarlimab/), [Mirvetuximab soravtansine](https://onco.cc/drugs/mirvetuximab-soravtansine/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- companies: [ARCAGY-GINECO](https://onco.cc/companies/arcagy-gineco/), [NRG Oncology](https://onco.cc/companies/nrg-oncology/)
- institutions: [National Cancer Institute (NIH)](https://onco.cc/institutions/nci/), [Society of Gynecologic Oncology](https://onco.cc/institutions/sgo/)
- trials: [GOG-0218 & ICON7 (bevacizumab)](https://onco.cc/trials/gog-0218-icon7/), [KEYNOTE-A18 / ENGOT-cx11 / GOG-3047](https://onco.cc/trials/keynote-a18/), [MIRASOL / GOG-3045](https://onco.cc/trials/mirasol/), [NRG-GY018 / KEYNOTE-868](https://onco.cc/trials/nrg-gy018-keynote-868/), [OUTBACK / ANZGOG 0902 / GOG-0274](https://onco.cc/trials/outback/), [RUBY / ENGOT-EN6 / GOG-3031](https://onco.cc/trials/ruby/)
- people: [Kathleen N. Moore](https://onco.cc/people/kathleen-moore/), [Ramez N. Eskander](https://onco.cc/people/ramez-eskander/), [Robert S. Mannel](https://onco.cc/people/robert-mannel/), [Thomas Herzog](https://onco.cc/people/thomas-herzog/)
- journals: [Gynecologic Oncology](https://onco.cc/journals/gynecologic-oncology/)

---
JSON: https://onco.cc/api/v1/entities/gog-foundation.json